#Japan #Osaka #Shionogi #Asverin #OTC Cough Relief

Shionogi Healthcare's Latest OTC Product Announcement

Shionogi Healthcare, based in Osaka, Japan, has officially announced the acquisition of manufacturing and marketing approval for its over-the-counter cough remedy, Asverin® Cough Relief Pro20. This approval was granted by the Ministry of Health, Labour and Welfare on January 15. The product mirrors its pharmaceutical counterpart, the prescription cough medicine Asverin® Tablets 20, which has been widely used in medical settings for its effective suppression of coughs and facilitation of mucus expulsion.

The active ingredient, Chipepidine Hydrobromide, is well-established in the medical community. Its effectiveness in alleviating cough symptoms has made it a trusted choice among healthcare professionals for years. The OTC version, Asverin® Cough Relief Pro20, is designed to offer the same dosage and benefits in a more accessible format for the general public. This new product marks the fourth addition to Shionogi's Pro Series of cough medicine, which emphasizes quality and reliability.

Features of Asverin® Cough Relief Pro20

Asverin® Cough Relief Pro20 is specially formulated for individuals aged eight and older, making it a suitable choice as a household medicine. One of the standout characteristics of this OTC product is its non-narcotic formulation, ensuring that it does not fall under any category of substances with potential for abuse or dependency. This focus on safety highlights Shionogi's commitment to consumer care and wellness.

While the exact launch date and product specifications are yet to be finalized, Shionogi Healthcare promises to keep consumers informed as new details emerge. The company remains dedicated to fostering healthier lifestyles by offering products that provide gentle, accurate, and enjoyable self-care solutions. Their mission aligns with their overarching philosophy of transforming the norms of healthcare, making it more accessible to everyone.

Shionogi Healthcare's Commitment to ESG Practices

In addition to product development, Shionogi Healthcare emphasizes its corporate responsibility through ESG (Environmental, Social, and Governance) initiatives. The company is determined to grow alongside society while fulfilling its commitments to sustainability. They focus on key Sustainable Development Goals (SDGs) such as ensuring health and well-being for all, promoting economic growth, and addressing inequalities and environmental issues.

Shionogi's efforts in the realm of ESG reflect their dedication to creating a positive impact on local and global scales, as they strive to address various social challenges through innovative healthcare solutions.

Engaging with the Community via Owned Media and Social Networks

To promote greater awareness and accessibility to personal care routines, Shionogi Healthcare utilizes various platforms including their owned media—Shionogi Healthcare ONLINE—and official social media accounts on X, Instagram, and LINE. Through these channels, they provide valuable information on products, campaigns, and self-care practices, fostering a community invested in health and wellness. Their online presence allows them to effectively reach consumers, making self-care more approachable and practical.

About Shionogi Healthcare

Founded on January 15, 2016, Shionogi Healthcare has evolved its business model to produce and sell OTC medicines, quasi-drugs, and health foods. With its commitment to excellence and continuous innovation, the company seeks to redefine personal healthcare. Headquartered in Osaka, Shionogi Healthcare aspires to lead the charge in transforming self-care into an integral part of everyday life for individuals everywhere.

For further information about Shionogi Healthcare and their products, visit their official website or follow them on their official X and Instagram channels.